CXCR5 and myelodysplastic syndrome: Xiao et al. [89] demonstrated that in MDS patients with autoimmune diseases, the proportion of CD4+CXCR5+ cells in peripheral blood increases while programmed death receptor 1 (PD1) expression decreases; conversely, treatment reduces the proportion of CD4+CXCR5+ cells and increases PD1 expression.